Page last updated: 2024-08-22

platinum and Carcinoma, Transitional Cell

platinum has been researched along with Carcinoma, Transitional Cell in 96 studies

Research

Studies (96)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (2.08)	18.7374
1990's	3 (3.13)	18.2507
2000's	2 (2.08)	29.6817
2010's	22 (22.92)	24.3611
2020's	67 (69.79)	2.80

Authors

Authors	Studies
Adib, E; Alva, AS; Curran, C; Diamantopoulos, LN; Grivas, P; Jain, RK; Kazakova, V; Marandino, L; Merchan, JR; Necchi, A; Plastini, TM; Sonpavde, G; Su, C; Tandon, A	1
Abe, T; Araki, H; Fujiwara, M; Hikami, K; Inokuchi, J; Ito, K; Kato, M; Kitamura, H; Kobayashi, T; Kojima, T; Kurahashi, R; Matsui, Y; Matsumoto, K; Nakamura, K; Nishiyama, H; Ogawa, K; Ogawa, O; Ozaki, Y; Sassa, N; Shimizu, K; Takahashi, A; Tashiro, Y; Tatarano, S; Tomida, R; Tsuchihashi, K; Uchida, J; Uegaki, M; Yamada, T; Yokomizo, A	1
Andresen, C; Bajorin, D; Burris, H; Daneshmand, S; De Giorgi, U; Galsky, M; Grivas, P; Gupta, S; Hoffman-Censits, J; Li, A; Lyou, Y; Moran, S; Pal, SK; Petrylak, D; Quinn, DI; Rearden, J; Rosenberg, JE; Vaishampayan, U; Xu, C	1
Hirayama, Y; Kato, M; Kuratsukuri, K; Otoshi, T; Takeyama, Y; Uchida, J; Yamamoto, S; Yamasaki, T; Yukimatsu, N	1
Bamias, A; Bell-McGuinn, KM; Castellano, D; de Wit, R; Drakaki, A; Fléchon, A; Gao, L; Lee, JL; Long, A; Matsubara, N; Necchi, A; Petrylak, DP; Powles, T; Sternberg, CN; van der Heijden, MS; Walgren, RA; Yu, EY; Zimmermann, AH	1
An, X; Hu, A; Huang, R; Li, H; Li, L; Ni, M; Shi, Y; Xue, C; Yang, W	1
Banna, GL; Calabro, F; Emeribe, U; Fléchon, A; Hellmis, E; Hotte, SJ; Lee, JL; Lima, AR; Loriot, Y; Marabelle, A; Miranda, PAP; Oh, SM; Pouessel, D; Powles, T; Roubaud, G; Shin, SJ; Sonpavde, GP; Sternberg, CN; Vera-Badillo, FE; Zagonel, V	1
Agarwal, N; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberón, MC	1
Balar, A; Campbell, M; Galsky, MD; Heath, EI; Hepp, Z; Mazerolle, F; McGregor, B; McKay, C; O'Donnell, PH; Petrylak, D; Quinn, DI; Regnault, A; Rosenberg, J; Steinberg, J; Yu, EY	1
Lacouture, ME; O'Donnell, PH; Patel, AB; Rosenberg, JE	1
Bajorin, DF; Braverman, J; Broughton, E; Galsky, MD; Gschwend, JE; Guo, S; Hamilton, M; Maira-Arce, M; Nasroulah, F; Shi, L; Witjes, JA; Ye, X	1
Hur, JY; Hwang, I; Jung, JY; Keam, B; Kim, C; Kim, HJ; Kim, IH; Lee, HJ; Lee, JL; Lee, MY; Maeng, CH; Park, I; Park, JH; Park, K; Park, SH	1
Bian, XJ; Cai, J; Chen, C; Han, W; He, C; Luo, H; Qu, YY; Sun, Z; Wang, Q; Xing, N; Ye, DW; Zhang, X; Zou, Q	1
Boellaard, TN; de Feijter, JM; Einerhand, SMH; Hendricksen, K; Schaake, EE; van de Kamp, MW; van der Heijden, MS; van Dijk, N; van Dorp, J; van Montfoort, ML; van Rhijn, BWG	1
Bamias, A; Caserta, C; Chang, J; Cislo, P; Climent Duran, MA; di Pietro, A; Fong, PC; Grivas, P; Kopyltsov, E; Park, SH; Parnis, FX; Powles, T; Su, PJ; Tournigand, C; Wang, J; Yamamoto, Y	1
Bajorin, DF; Castellano, D; Dao, TV; Dry, H; Howells, K; Kozlov, V; Lanasa, MC; Li, JR; Mukherjee, SD; Park, SH; Rosenberg, JE; Stewart, R	1
Chen, X; Lin, T; Liu, S	1
Anari, F; Geynisman, DM; Ghatalia, P; Handorf, E; Miron, B; Plimack, ER; Zarrabi, K; Zibelman, MR	1
Einerhand, SMH; van der Heijden, MS; van Dijk, N; van Rhijn, BWG	1
Takahashi, T	1
Barber, J; Birtle, AJ; Brock, S; Crabb, SJ; Dempsey, L; Enting, D; Faust, G; Frew, J; Gale, J; Hinsley, S; Hussain, S; Jones, RJ; Lees, K; McGovern, U; Parikh, O; Powles, T; Ratnayake, G; Song, Y; Soulis, E; Sundar, S; Trevethan, A	1
Inokuchi, J; Ito, K; Kawahara, T; Kita, Y; Kitamura, H; Kobayashi, T; Kurahashi, R; Maruyama, S; Matsumoto, K; Morita, S; Mukai, S; Otsuka, H; Ozaki, Y; Sano, T; Segawa, T; Takahashi, A; Tomida, R; Tsutsumi, M; Uegaki, M	1
Charchanti, A; Chatzopoulos, K; Christodoulou, C; Fostira, F; Foukas, P; Fountzilas, G; Goussia, A; Koliou, GA; Kotoula, V; Koumarianou, A; Nifora, M; Papadopoulou, K; Pectasides, D; Psyrri, A; Samantas, E; Tsiatas, M; Tsimiliotis, D; Visvikis, A	1
Adachi, T; Azuma, H; Egawa, S; Fukuokaya, W; Fukushima, T; Hashimoto, T; Inamoto, T; Iwatani, K; Kimura, T; Komura, K; Miki, J; Mori, K; Nakamori, K; Nakamura, K; Nishimura, K; Nishio, K; Ohno, Y; Shiroki, R; Takahara, K; Tsuduki, S; Uchimoto, T; Urabe, F; Yamamoto, S; Yanagisawa, T; Yano, Y; Yoshizawa, A	1
Abe, H; Fukuokaya, W; Hashimoto, M; Imai, Y; Ito, K; Iwatani, K; Kimura, S; Kimura, T; Koike, Y; Miki, J; Onuma, H; Oyama, Y; Tsuzuki, S; Urabe, F; Yamamoto, S; Yanagisawa, T	1
Aieta, M; Atzori, F; Bimbatti, D; Carella, C; De Giorgi, U; Di Maio, M; Di Napoli, M; Ermacora, P; Gamba, T; Giannatempo, P; Hamzaj, A; Ignazzi, G; Lolli, C; Masini, C; Pierantoni, F; Pignata, S; Procopio, G; Santini, D; Scandurra, G; Stellato, M; Tambaro, R; Veccia, A; Vignani, F; Zonno, A	1
Ikeda, M; Iwamura, M; Katsumata, H; Koguchi, D; Matsumoto, K; Nakamura, M; Sato, Y; Shimizu, Y; Shiono, Y	1
Plimack, ER; Zibelman, MR	1
Bonnet, I; Boutrois, J; Brachet, PE; Castera, M; Clarisse, B; Coquan, E; Goardon, N; Grellard, JM; Joly, F; Lequesne, J; Meriaux, E; Nevière, Z; Thiery-Vuillemin, A; Travers, R	1
Goto, Y	1
Ito, K; Kita, Y; Kobayashi, T	1
Azuma, H; Harada, KI; Inamoto, T; Ishikawa, G; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sano, A; Sato, R; Sugiyama, T; Takemura, A; Tamura, K; Tanaka, H; Uchimoto, T; Watanabe, H; Watanabe, K	1
Matsumoto, H	1
Baretton, G; Bolenz, C; Foller, S; Grimm, MO; Grün, CB; Leucht, K; Loidl, W; Meran, J; Niegisch, G; Pichler, M; Roghmann, F; Schmitz, M; Schmitz-Dräger, B; Schostak, M; Schumacher, U; Zengerling, F	1
Chan, TTW; Desai, C; di Pietro, A; Eto, M; Gao, S; Gurney, H; Lee, JL; Park, SH; Sandner, R; Su, PJ; Tsuchiya, N; Wang, J	1
Ajmera, M; Bellmunt, J; Candrilli, SD; Cappelleri, JC; Chang, J; Costa, N; Esterberg, E; Hitchens, A; Kearney, M; Pavilack-Kirker, M	1
Albers, P; Bannowsky, A; Becht, E; Fischer, C; Heinzelbecker, J; Hofmann, R; Kamradt, J; Kuehn, M; Langbein, S; Lehmann, J; Müller, M; Retz, M; Spieler, N; Steiner, G; Stoeckle, M; Volkmer, B; von Rundstedt, F; Wagenpfeil, G; Weber, HM; Wellek, S	1
Foller, S; Grimm, MO; Leeder, M; Leucht, K	1
Chen, R; Li, H; Wang, J; Wen, R; Zhou, J; Zhu, J	1
Agarwal, N; Bakaloudi, DR; Bamias, A; Barrera, RM; Brown, JR; Buznego, LA; Carballeira, CC; Castellano, D; Diamantopoulos, LN; Drakaki, A; Duran, I; Frobe, A; Grivas, P; Gupta, S; Jindal, T; Johnson, J; Khaki, AR; Korolewicz, J; Koshkin, VS; Lin, GI; Makrakis, D; Marmorejo, D; McKay, RR; Miletić, M; Murgić, J; Pinato, DJ; Rey-Cárdenas, M; Rodriguez-Vida, A; Ruplin, AT; Stewart, T; Talukder, R; Tripathi, N; Yu, EY; Zakharia, Y; Zakopoulou, R	1
Bhanegaonkar, A; Bilen, MA; Kim, R; Liu, FX; Peng, J; Robinson, SB; Schroeder, A	1
Augusto, I; Cruz, A; Mansinho, A; Marconi, L; Pinto, C	1
Benedict, A; Chang, J; Chou, P; Goh, C; Kapetanakis, V; Kearney, M; Kuo, K; Lin, AY; Liu, K; Palencia, R; Su, PJ; Wu, E; Xiao, Y	1
Bamias, A; Castellano, D; Drakaki, A; DuPree, K; Fléchon, A; Friedlander, T; Gomez-Roca, C; Joly Lobbedez, F; Lee, JL; Martin-Liberal, J; Michielin, F; Morales-Barrera, R; Moreno-Candilejo, I; Park, C; Powles, T; Rishipathak, D; Shemesh, CS; Shin, SJ; Steinberg, EE; Tosi, D; Williams, P; Young, F; Yuen, K	1
Burns, KD; Carroll Bullock, A; Conway, D; Devgan, G; Kehoe, K; Lapuente, M; Wood, LS	1
Akiyama, Y; Ambe, Y; Enomoto, Y; Fujimura, T; Fukuhara, H; Furuya, Y; Kakutani, S; Kamei, J; Kaneko, T; Kawai, T; Kishitani, K; Kume, H; Miyakawa, J; Nakagawa, T; Nakamura, Y; Nishimatsu, H; Noda, M; Obinata, D; Sato, Y; Sugimoto, K; Taguchi, S; Takahashi, S; Uemura, Y; Yamada, D; Yamada, Y; Yamaguchi, K	1
Alt, M; Goluboff, ET; Kazeem, G; Lin, Y; Sridhar, SS; Stecca, C	1
Hashimoto, T	1
Lotan, Y; Meng, X	1
Burki, TK	1
Cathomas, R; Fear, S; Haefeli, J; Llado, A; Mach, N; Pless, M; Riklin, C; Schardt, J; Stenner, F	1
Collette, S; Galsky, MD; Grossfeld, G; Han, GC; Necchi, A; Saci, A; Sharma, P; Siefker-Radtke, A; Szabo, PM	1
Hayakawa, N; Kikuchi, E	1
Al-Ahmadie, H; Bajorin, DF; Balar, AV; Bochner, BH; Dalbagni, G; Funt, SA; Iyer, G; Lee, CH; Li, HA; Milowsky, MI; Mota, JM; Ostrovnaya, I; Pietzak, E; Rosenberg, JE; Solit, DB; Teo, MY; Whiting, KA	1
Agrawal, M; Aljumaily, R; Apolo, AB; Dirix, L; Ellerton, JA; Gordon, MS; Gourdin, T; Gulley, JL; Infante, JR; Lee, KW; Manitz, J; Patel, MR; Pennock, G; Ravaud, A; Ruisi, M; Schöffski, P; Taylor, MH; Wang, D	1
Funada, S; Luo, Y; Yoshioka, T	1
Alfred Witjes, J	1
Black, PC; Contreras-Sanz, A; Roumiguie, M	1
Bokal, U; Mangaroski, D; Mencinger, M	1
Bamias, A; Calabrò, F; Castellano, D; Choy, E; de Velasco, G; James, N; Kramer, M; Lopez-Rios, F; Loriot, Y; Merseburger, AS; Sternberg, CN; Tzannis, K; Zakopoulou, R	1
Agarwal, A; Barata, P; Bilen, MA; Curran, C; Drakaki, A; Garcia, J; Grivas, P; Gupta, R; Hussain, SA; Kanesvaran, R; Lee, JL; Lorenzo, GD; Ornstein, M; Pond, GR; Sonpavde, G; Verolino, P	1
Alessi, A; Briganti, A; Calareso, G; Colecchia, M; Madison, R; Marandino, L; Martini, A; Montorsi, F; Necchi, A; Raggi, D; Ross, JS	1
Habuchi, T; Hashimoto, Y; Hatakeyama, S; Kobayashi, M; Muto, Y; Narita, S; Narita, T; Noro, D; Numakura, K; Ohyama, C; Saito, M; Tanaka, T; Tokui, N; Yoneyama, T	1
Fujimoto, N; Harada, M; Inatomi, H; Minato, A; Onishi, R; Terado, M; Tomisaki, I	1
Yuasa, T	1
Bellmunt, J; Crabb, SJ; De Giorgi, U; Do, OA; Dorff, TB; Ferris, LA; Galsky, MD; Harshman, LC; Holt, SK; Ladoire, S; Necchi, A; Niegisch, G; Pal, SK; Ramos, JD; Srinivas, S; Sternberg, CN; Vaishampayan, UN; Wong, RL; Yu, EY	1
Ohlmann, CH; Retz, M; Rexer, H	1
Fu, W; Goldberg, KB; Kim, G; Liu, Q; Maher, VE; Ning, YM; Palmby, T; Pazdur, R; Ricks, T; Suzman, D; Tang, S; Zhang, L	1
Biasoni, D; Catanzaro, M; Colecchia, M; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Perrone, F; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Torelli, T	1
Agarwal, N; Bamias, A; Baniel, J; Bellmunt, J; Berthold, DR; Bowles, DW; Crabb, S; Galsky, MD; Harshman, LC; Ladoire, S; Necchi, A; Niegisch, G; Pal, SK; Plimack, ER; Pond, GR; Powles, T; Rosenberg, JE; Srinivas, S; Yu, EY	1
Hirayama, T; Ikeda, M; Irie, A; Iwamura, M; Koguchi, D; Matsuda, D; Matsumoto, K; Murakami, Y; Okuno, N; Taoka, Y; Utsunomiya, T	1
Di Nunno, V; Massari, F	2
Bellmunt, J; Hoffman-Censits, J; Kaiser, C; Pal, SK; Tayama, D; Zheng, H	1
Perez-Gracia, JL	1
Al-Ahmadie, H; Arcila, ME; Bajorin, DF; Bambury, RM; Bellmunt, J; Berger, MF; Bochner, BH; Bouvier, N; Boyd, ME; Cha, EK; Hyman, DM; Iyer, G; Jordan, E; Mullane, SA; Ostrovnaya, I; Roper, N; Rosenberg, JE; Solit, DB; Teo, MY; Zabor, EC	1
Agarwal, N; Tripathi, A	1
Albertson, DJ; Butterfield, A; Cairns, BR; Dalley, B; Gupta, S; Lowrance, WT; O'Shea, JM; Pappas, LM; Parnell, TJ; Schiffman, JD; Sharma, S; Weston, A	1
Booth, CM; Tannock, IF; Vera-Badillo, FE	1
Banu, E; Bay, JO; Beuzeboc, P; Culine, S; Deplanque, G; Elaidi, R; Goldwasser, F; Gravis, G; Machiels, JP; Muracciole, X; Nguyen, T; Oudard, S; Pichon, MF; Priou, F; Radvanyi, F; Ravaud, A; Teghom, C; Théodore, C; Vannetzel, JM; Vano, Y; Vieillefond, A; Voog, E	1
Apollo, A; Bajorin, DF; Bambury, RM; Benjamin, DJ; Chaim, JL; Garcia-Grossman, IR; Iyer, G; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Sullivan, J; Voss, MH; Xiao, H; Zabor, EC	1
Bellmunt, J; Choueiri, TK; Guancial, EA; Kantoff, PW; Lis, RT; Loda, M; Mullane, SA; Rosenberg, J; Stack, EC; Werner, L	1
Bochner, BH	1
Chang, SS	1
Arranz, JÁ; Azrilevich, A; Baron, A; Bedke, J; Bracarda, S; Galsky, MD; Grimm, MO; Krishnan, S; Lambert, A; Necchi, A; Ohyama, C; Pal, S; Plimack, ER; Qu, X; Retz, M; Saci, A; Sharma, P; Siefker-Radtke, A; Vaena, D	1
Alici, S; Berk, V; Camcı, C; Coskun, U; Degerli, H; Gumus, M; Kaya, AO; Kefeli, U; Oner, MK; Ozdemir, NY; Ozkan, M; Ozturk, C; Sevinc, A; Unal, OU; Yilmaz, AU	1
Matsuda, T; Mikami, O; Oguchi, N; Okada, H; Uchida, J	1
Koga, H; Kotoh, S; Naito, S; Nakashima, M; Tanaka, M; Yokomizo, A	1
Albiol, S; Bellmunt, J	1
Matsuyama, H; Sakatoku, J; Shimabukuro, T; Wada, T; Yamamoto, N; Yoshihiro, S	1
Iwamoto, Y; Sugioka, Y	1
Aoki, K; Baba, T; Hasuda, K; Kuroiwa, T; Taniguchi, S	1
deKernion, JB; Persky, L; Rose, D; Soloway, MS	1

Reviews

9 review(s) available for platinum and Carcinoma, Transitional Cell

Article	Year
Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis. Clinical immunology (Orlando, Fla.), 2022, Volume: 236 Topics: Carcinoma, Transitional Cell; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Male; Platinum; Programmed Cell Death 1 Receptor; Urinary Bladder Neoplasms	2022
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Immunologic Factors; Immunotherapy; Male; Platinum; Urinary Bladder Neoplasms	2022
Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives. Journal of advanced research, 2022, Volume: 39 Topics: Carcinoma, Transitional Cell; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Platinum; Tumor Microenvironment; Urinary Bladder Neoplasms	2022
Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-01, Volume: 41, Issue:1 Topics: Carcinoma, Transitional Cell; Cisplatin; Humans; Platinum; Urinary Bladder Neoplasms	2023
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients. International journal of urology : official journal of the Japanese Urological Association, 2023, Volume: 30, Issue:9 Topics: Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms	2023
[Antibody-drug conjugates as new therapeutic agents in uro-oncology]. Urologie (Heidelberg, Germany), 2023, Volume: 62, Issue:7 Topics: Carcinoma, Transitional Cell; Humans; Immunoconjugates; Immunotherapy; Platinum; Urinary Bladder Neoplasms	2023
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma. Advances in therapy, 2023, Volume: 40, Issue:10 Topics: B7-H1 Antigen; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Platinum; Urinary Bladder Neoplasms	2023
Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma. Clinical journal of oncology nursing, 2023, 01-25, Volume: 27, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms	2023
New chemotherapy combinations for advanced bladder cancer. Current opinion in urology, 2001, Volume: 11, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Female; Gemcitabine; Humans; Male; Methotrexate; Neoplasm Metastasis; Platinum; Prognosis; Severity of Illness Index; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Vinblastine	2001

Trials

26 trial(s) available for platinum and Carcinoma, Transitional Cell

Article	Year
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. British journal of clinical pharmacology, 2022, Volume: 88, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Platinum; Ramucirumab; Urinary Bladder Neoplasms	2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. European journal of cancer (Oxford, England : 1990), 2022, Volume: 163 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Male; Platinum; Urinary Bladder Neoplasms; Urinary Tract; Urologic Neoplasms	2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. European urology, 2022, Volume: 81, Issue:5 Topics: Adult; Antibodies, Monoclonal; Carcinoma, Transitional Cell; Fatigue; Female; Humans; Immune Checkpoint Inhibitors; Male; Pain; Platinum; Programmed Cell Death 1 Receptor; Quality of Life; Urinary Bladder Neoplasms	2022
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. The oncologist, 2022, 03-11, Volume: 27, Issue:3 Topics: Antibodies, Monoclonal; Carcinoma, Transitional Cell; Cell Adhesion Molecules; Female; Humans; Immunoconjugates; Male; Nectins; Platinum; Programmed Cell Death 1 Receptor; Urologic Neoplasms	2022
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial. European urology oncology, 2022, Volume: 5, Issue:5 Topics: B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Muscles; Nivolumab; Platinum; Programmed Cell Death 1 Receptor; Quality of Life; Urinary Bladder Neoplasms	2022
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study. Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Indoles; Male; Platinum; Pyrroles; Urinary Bladder Neoplasms	2022
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer. International journal of cancer, 2022, Dec-01, Volume: 151, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Ipilimumab; Neoadjuvant Therapy; Nivolumab; Platinum; Urinary Bladder Neoplasms	2022
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. European urology, 2023, Volume: 83, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Patient Reported Outcome Measures; Platinum; Quality of Life; Urinary Bladder; Urinary Bladder Neoplasms	2023
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-01, Volume: 41, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Phthalazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Urinary Bladder Neoplasms	2023
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-01, Volume: 41, Issue:1 Topics: Adenosine Diphosphate Ribose; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Transitional Cell; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerases; Urinary Bladder Neoplasms	2023
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. European urology, 2023, Volume: 83, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; Humans; Maintenance Chemotherapy; Platinum; Progression-Free Survival; Urinary Bladder Neoplasms	2023
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma. BMC cancer, 2022, Nov-24, Volume: 22, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Male; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; Urinary Bladder Neoplasms	2022
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial. The Lancet. Oncology, 2023, Volume: 24, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Immunotherapy; Ipilimumab; Male; Middle Aged; Nivolumab; Platinum; Urinary Bladder Neoplasms	2023
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis. Urologic oncology, 2023, Volume: 41, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Humans; Platinum; Urinary Bladder; Urinary Bladder Neoplasms	2023
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial. Urologic oncology, 2023, Volume: 41, Issue:8 Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Follow-Up Studies; Gemcitabine; Humans; Platinum; Quality of Life; Urinary Bladder; Urinary Bladder Neoplasms	2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 11-01, Volume: 29, Issue:21 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms	2023
Aktuelle Urologie, 2023, Volume: 54, Issue:6 Topics: Carcinoma, Transitional Cell; Humans; Immunologic Factors; Platinum; Urinary Bladder; Urinary Bladder Neoplasms	2023
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-01, Volume: 26, Issue:19 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Transitional Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Nivolumab; Platinum; Progression-Free Survival; Tumor Burden; Urothelium	2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. Journal for immunotherapy of cancer, 2020, Volume: 8, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Platinum	2020
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. ESMO open, 2021, Volume: 6, Issue:3 Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Platinum; Prospective Studies; Urinary Tract	2021
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial. Clinical genitourinary cancer, 2021, Volume: 19, Issue:5 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Pyridines; Urinary Bladder Neoplasms	2021
[First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metas Der Urologe. Ausg. A, 2017, Volume: 56, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Therapy, Combination; Humans; Platinum; Treatment Outcome; Urologic Neoplasms; Urothelium	2017
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. European urology, 2018, Volume: 73, Issue:5 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome; United States; Urologic Neoplasms	2018
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:1 Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Platinum; Receptor, ErbB-2; Trastuzumab	2015
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Platinum; Prognosis; Survival Rate; Urologic Neoplasms	2017
[Study on platinum concentration in internal iliac venous blood after iliac artery cisplatin infusion for invasive bladder cancer]. Hinyokika kiyo. Acta urologica Japonica, 1999, Volume: 45, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Female; Humans; Iliac Vein; Male; Methotrexate; Middle Aged; Platinum; Urinary Bladder Neoplasms; Vinblastine	1999

Other Studies

61 other study(ies) available for platinum and Carcinoma, Transitional Cell

Article	Year
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. Clinical genitourinary cancer, 2022, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Carcinoma, Transitional Cell; Female; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Platinum; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms	2022
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. International journal of urology : official journal of the Japanese Urological Association, 2021, Volume: 28, Issue:12 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2021
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clinical genitourinary cancer, 2022, Volume: 20, Issue:1 Topics: Carcinoma, Transitional Cell; Female; Humans; Male; Phenylurea Compounds; Platinum; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Salvage Therapy; Urinary Bladder Neoplasms	2022
A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma. Urologic oncology, 2022, Volume: 40, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Male; Middle Aged; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2022
Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. Current problems in cancer, 2022, Volume: 46, Issue:3 Topics: Carcinoma, Transitional Cell; Humans; Hypoalbuminemia; Immune Checkpoint Inhibitors; Platinum; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms	2022
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. Urologic oncology, 2022, Volume: 40, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Immune Checkpoint Inhibitors; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2022
Reply to: Comments on "Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer". International journal of cancer, 2022, 11-15, Volume: 151, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Immunotherapy; Neoadjuvant Therapy; Platinum; Urinary Bladder Neoplasms	2022
Comments on "Survival after neoadjuvant/induction combination immunotherapy versus combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer". International journal of cancer, 2022, 11-15, Volume: 151, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Immunotherapy; Neoadjuvant Therapy; Platinum; Urinary Bladder Neoplasms	2022
Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias. Cancer science, 2022, Volume: 113, Issue:11 Topics: Antineoplastic Agents, Immunological; Carcinoma, Transitional Cell; Humans; Nivolumab; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2022
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens. Urologic oncology, 2022, Volume: 40, Issue:12 Topics: B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Transitional Cell; CD8-Positive T-Lymphocytes; Humans; Lymphocytes, Tumor-Infiltrating; Platinum; Prognosis; Urinary Bladder Neoplasms; Xeroderma Pigmentosum Group D Protein	2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma. BJU international, 2023, Volume: 131, Issue:4 Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Methotrexate; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine	2023
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma. Cancer immunology, immunotherapy : CII, 2023, Volume: 72, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms	2023
Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy. International journal of molecular sciences, 2022, Oct-11, Volume: 23, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Transitional Cell; Cisplatin; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Paclitaxel; Phosphoglycerate Kinase; Platinum; Retrospective Studies	2022
Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients. International journal of urology : official journal of the Japanese Urological Association, 2023, Volume: 30, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms	2023
Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab. International journal of urology : official journal of the Japanese Urological Association, 2023, Volume: 30, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Progression-Free Survival	2023
Editorial Comment to Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab. International journal of urology : official journal of the Japanese Urological Association, 2023, Volume: 30, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Therapy, Combination; Humans; Platinum; Progression-Free Survival	2023
Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review. Clinical genitourinary cancer, 2023, Volume: 21, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Male; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2023
The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma. Urologic oncology, 2023, Volume: 41, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Humans; Middle Aged; Platinum; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms	2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. Clinical genitourinary cancer, 2023, Volume: 21, Issue:5 Topics: Antibodies, Monoclonal; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2023
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study). The oncologist, 2023, 09-07, Volume: 28, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Humans; Medicare; Platinum; Retrospective Studies; United States; Urinary Bladder Neoplasms	2023
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan. Cancer reports (Hoboken, N.J.), 2023, Volume: 6, Issue:10 Topics: Carcinoma, Transitional Cell; Cost-Effectiveness Analysis; Humans; Platinum; Taiwan; Urinary Bladder Neoplasms	2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. International journal of urology : official journal of the Japanese Urological Association, 2023, Volume: 30, Issue:12 Topics: Carcinoma, Transitional Cell; Humans; Platinum; Propensity Score; Urinary Bladder Neoplasms	2023
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma. BMC cancer, 2023, Sep-29, Volume: 23, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Hemoglobins; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2023
Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. International journal of urology : official journal of the Japanese Urological Association, 2023, Volume: 30, Issue:12 Topics: Carcinoma, Transitional Cell; Humans; Platinum; Propensity Score; Urinary Bladder Neoplasms	2023
Enfortumab Vedotin Checks Urothelial Cancer. Cancer discovery, 2019, Volume: 9, Issue:10 Topics: Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms	2019
Critical treatment choices for patients with platinum-refractory urothelial carcinoma. The Lancet. Oncology, 2020, Volume: 21, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Docetaxel; Double-Blind Method; Humans; Platinum; Ramucirumab; Urologic Neoplasms	2020
Enfortumab vedotin shows promise in solid tumours. The Lancet. Oncology, 2020, Volume: 21, Issue:3 Topics: Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Platinum	2020
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice. Swiss medical weekly, 2020, May-04, Volume: 150 Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Switzerland; Urinary Bladder Neoplasms	2020
Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer. The Lancet. Oncology, 2020, Volume: 21, Issue:8 Topics: Anilides; Carcinoma, Transitional Cell; Humans; Platinum; Pyridines; Urologic Neoplasms	2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European urology, 2020, Volume: 78, Issue:6 Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Receptor, Fibroblast Growth Factor, Type 3; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms	2020
Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer. JAMA oncology, 2021, 04-01, Volume: 7, Issue:4 Topics: Albumins; Canada; Carcinoma, Transitional Cell; Humans; Paclitaxel; Platinum	2021
Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. European urology, 2021, Volume: 80, Issue:1 Topics: B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Immune Checkpoint Inhibitors; Platinum; Prognosis; Urinary Bladder Neoplasms; Urologic Neoplasms	2021
Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur European urology, 2021, Volume: 79, Issue:6 Topics: Carcinoma, Transitional Cell; Cisplatin; Humans; Mutation; Platinum; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms	2021
Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice. Radiology and oncology, 2021, 05-04, Volume: 55, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Prognosis; Survival Analysis; Urologic Neoplasms	2021
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. Clinical genitourinary cancer, 2021, Volume: 19, Issue:5 Topics: Aged; B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Nivolumab; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2021
Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study. International journal of urology : official journal of the Japanese Urological Association, 2021, Volume: 28, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms	2021
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer. International journal of urology : official journal of the Japanese Urological Association, 2021, Volume: 28, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms	2021
Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer. International journal of urology : official journal of the Japanese Urological Association, 2021, Volume: 28, Issue:9 Topics: Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum	2021
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. The oncologist, 2021, Volume: 26, Issue:12 Topics: Carcinoma, Transitional Cell; Humans; Platinum; Progression-Free Survival; Retrospective Studies; Urinary Bladder Neoplasms	2021
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. The oncologist, 2017, Volume: 22, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Drug Approval; Female; Humans; Male; Middle Aged; Platinum; Response Evaluation Criteria in Solid Tumors; Risk Assessment; Treatment Outcome; United States; United States Food and Drug Administration; Urologic Neoplasms; Urothelium	2017
Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. Clinical genitourinary cancer, 2018, Volume: 16, Issue:2 Topics: Aged; B7-H1 Antigen; Carcinoma, Transitional Cell; Chromosomes, Human, X; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Platinum; Receptors, Androgen; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome; Urologic Neoplasms	2018
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical genitourinary cancer, 2018, Volume: 16, Issue:2 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Humans; Male; Middle Aged; Platinum; Prognosis; Retrospective Studies; Treatment Outcome; Urologic Neoplasms	2018
Selected High-Risk Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy for Adjuvant Chemotherapy: A Multi-Institutional Retrospective Study. Clinical genitourinary cancer, 2018, Volume: 16, Issue:3 Topics: Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Patient Selection; Platinum; Prognosis; Retrospective Studies; Urologic Neoplasms	2018
Atezolizumab for platinum-treated metastatic urothelial carcinoma. Lancet (London, England), 2018, 02-24, Volume: 391, Issue:10122 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms	2018
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8. European urology, 2018, Volume: 74, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms	2018
Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number European urology, 2018, Volume: 74, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms	2018
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma." Urologic oncology, 2018, Volume: 36, Issue:7 Topics: Carcinoma, Transitional Cell; DNA Damage; Humans; Mutation; Platinum; Urologic Neoplasms	2018
Editorial Comment. The Journal of urology, 2018, Volume: 200, Issue:6 Topics: Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms	2018
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in Molecular cancer therapeutics, 2019, Volume: 18, Issue:1 Topics: Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Mutation; Nuclear Proteins; Platinum; Precision Medicine; Transcription Factors; Urinary Bladder Neoplasms	2019
Aktuelle Urologie, 2019, Volume: 50, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; United States; Urologic Neoplasms	2019
Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-10, Volume: 37, Issue:29 Topics: Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Immunotherapy; Platinum; Randomized Controlled Trials as Topic	2019
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. The oncologist, 2015, Volume: 20, Issue:5 Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium	2015
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:4 Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma, Transitional Cell; DNA Repair; DNA-Binding Proteins; Endonucleases; Fanconi Anemia Complementation Group Proteins; Female; Humans; Male; Membrane Proteins; Neoplasm Metastasis; Neoplasm Proteins; Platinum; Poly (ADP-Ribose) Polymerase-1; Prospective Studies; Rad51 Recombinase; Survival Analysis; Treatment Outcome; Urologic Neoplasms	2016
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial. European urology, 2017, Volume: 71, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms	2017
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed following Treatment with Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial. The Journal of urology, 2016, Volume: 196, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms	2016
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy. Onkologie, 2012, Volume: 35, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Platinum; Premedication; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult	2012
Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines. International journal of oncology, 2000, Volume: 16, Issue:5 Topics: Carcinoma, Transitional Cell; Cisplatin; Drug Resistance, Neoplasm; Humans; Platinum; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2000
[Angiographic analysis of intratumoral Pt concentration on intra-arterial infusion therapy for bladder cancer]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1991, Volume: 82, Issue:7 Topics: Aged; Angiography; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Invasiveness; Platinum; Regional Blood Flow; Urinary Bladder; Urinary Bladder Neoplasms	1991
Comparison of the effects of intra-arterial and intravenous cisplatin on both limb tumor and lung metastases of transitional cell carcinoma RBT-1 in rats. Chemotherapy, 1990, Volume: 36, Issue:4 Topics: Animals; Carcinoma, Transitional Cell; Cisplatin; Female; Hindlimb; Infusions, Intra-Arterial; Infusions, Intravenous; Kidney; Lung; Lung Neoplasms; Neoplasm Transplantation; Platinum; Rats; Rats, Inbred Strains	1990
Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, in combination with angiotensin II in a rat limb tumor. Cancer research, 1987, Jul-15, Volume: 47, Issue:14 Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Carcinoma, Transitional Cell; Cisplatin; Female; Infusions, Intra-Arterial; Kidney; Neoplasm Transplantation; Platinum; Rats; Rats, Inbred Strains; Thiosulfates; Tissue Distribution; Urinary Bladder Neoplasms	1987
Effect of chemotherapeutic agents on bladder cancer: a new animal model. Surgical forum, 1973, Volume: 24 Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Dactinomycin; Diamines; Disease Models, Animal; Doxorubicin; Fluorouracil; Hydroxyurea; Lomustine; Mice; Mice, Inbred C3H; Platinum; Urinary Bladder Neoplasms	1973